Powered by
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) has sold 32,142,858 additional shares of its common stock to the public for $225 million, before deducting underwriting discounts, commissions, and other offering expenses. …
ANN ARBOR — The Ann Arbor pharmaceutical developer Esperion Therapeutics Inc. (Nasdaq: ESPR) said it would offer 1.75 million new shares of the company to the public at a price …
ANN ARBOR — Turns out there was no problem with the demand for stock in the Ann Arbor cholesterol-busting drug developer Esperion Therapeutics Inc. (Nasdaq: ESPR). The company announced Tuesday …
ANN ARBOR — Esperion Therapeutics Inc. (Nasdaq: ESPR) has priced the offering of 4.25 million shares of its common stock at $20 a share. The offering is expected to provide $85 …
ANN ARBOR — Esperion Theapeutics Inc. (Nasdaq: ESPR), the developer of a new class of cholesterol-fighting drugs, has announced the intention to sell $85 million of its stock in a …
ANN ARBOR — The defense and simulation product developer Arotech Corp. (NasdaqGM: ARTX) says the underwriter of its recent public stock offering of 2.86 million shares has exercised in full …
ANN ARBOR — The Ann Arbor electronics and optics manufacturer Advanced Photonix Inc. (NYSE: API) said it has priced a public stock offering of almost 5.4 million shares at 53 cents per …